COMP <GO>
OCUL vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
Ocular Therapeutix Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: OCUL 1
— MRK 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $6.97 (-4.65%) • MKT CAP: $1.61B
roic
-35.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OCUL VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OCUL | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.30% | 74.80% | +12.50 | OCUL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -13.51% | 3.42% | -16.93 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -18.50% | 1.30% | -19.80 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.31 | 5.19 | -0.88 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.5 | 51.7 | -4.20 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.61B | $361.02B | -$359.42B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OCUL REV | MRK REV | OCUL GROSS % | MRK GROSS % | OCUL FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $52.0M | $65.01B | 87.3% | 74.8% | -$216.9M | $12.36B |
| FY 2024 | $63.7M | $64.17B | 91.2% | 76.3% | -$136.0M | $18.10B |
| FY 2023 | $58.4M | $60.12B | — | — | -$70.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OCUL // BETA —
MRK // BETA 0.92